

Development of 19S RP UCHL5 inhibitors for the treatment of relapsed and refractory multiple myeloma

Korea Research Institute of Bioscience and Biotechnology (KRIBB)



ONCOLOGY	Lead
Product Type	Chemical – Small Molecule
Indication	Multiple myeloma
Target	UCHL5
MoA(Mechanism of Action)	Inhibition of deubiquitinase activity of UCHL5 induces accumulation of unfolded proteins, which leads to ER stress-mediated apoptosis
Competitiveness	Overcome the resistance to proteasome inhibitors, including bortezomib and carfilzomib
Development Stage	Lead
Route of Administration	Oral Route